Investing.com -- Novo Nordisk A/S (NYSE: NVO) stock dropped 2.1% premarket following news that Spain’s health ministry has requested clarification about the company’s obesity awareness campaign, which ...

With patents expiring and the obesity market opening up, major players in the weight-loss market are lining up to see what will follow the likes of Wegovy and Zepbound. With Morgan Stanley estimating ...

A large study led by researchers at Case Western Reserve University suggests that semaglutide—a drug already popular for ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...

So-called ‘skinny jabs’ are being prescribed to people who don’t need them, with terrifying side effects. How did our ...

Novo Nordisk (NYSE: NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced ...

A blockbuster diabetes and weight-loss drug might be doing more than controlling blood sugar—it could also be protecting the ...

A unique business structure gives LifeMD access to the growing GLP-1 marketplace that can help boost the heavily shorted stock price. Read an analysis of LFMD here.

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in ...

A new study suggests that popular weight loss medications could significantly benefit patients awaiting kidney transplants.

A massive U.S. study found diabetics on semaglutide (Ozempic’s active ingredient) had up to 70% lower risk of ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...